224 related articles for article (PubMed ID: 20126646)
1. Bacterial pneumonia among HIV-infected patients: decreased risk after tobacco smoking cessation. ANRS CO3 Aquitaine Cohort, 2000-2007.
Bénard A; Mercié P; Alioum A; Bonnet F; Lazaro E; Dupon M; Neau D; Dabis F; Chêne G;
PLoS One; 2010 Jan; 5(1):e8896. PubMed ID: 20126646
[TBL] [Abstract][Full Text] [Related]
2. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study.
Kohli R; Lo Y; Homel P; Flanigan TP; Gardner LI; Howard AA; Rompalo AM; Moskaleva G; Schuman P; Schoenbaum EE;
Clin Infect Dis; 2006 Jul; 43(1):90-8. PubMed ID: 16758423
[TBL] [Abstract][Full Text] [Related]
3. Incidence, timing, and determinants of bacterial pneumonia among HIV-infected patients: data from the ICONA Foundation Cohort.
Mussini C; Galli L; Lepri AC; De Luca A; Antinori A; Libertone R; Angarano G; Bonfanti P; Castagna A; DʼArminio Monforte A;
J Acquir Immune Defic Syndr; 2013 Jul; 63(3):339-45. PubMed ID: 23591636
[TBL] [Abstract][Full Text] [Related]
4. Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort.
Bruyand M; Thiébaut R; Lawson-Ayayi S; Joly P; Sasco AJ; Mercié P; Pellegrin JL; Neau D; Dabis F; Morlat P; Chêne G; Bonnet F;
Clin Infect Dis; 2009 Oct; 49(7):1109-16. PubMed ID: 19705973
[TBL] [Abstract][Full Text] [Related]
5. Determinants of smoking cessation attempts among HIV-infected patients results from a hospital-based prospective cohort.
Encrenaz G; Bénard A; Rondeau V; Bonnet F; Lazaro E; Neau D; Dupon M; Dabis F; Mercié P; Chêne G;
Curr HIV Res; 2010 Apr; 8(3):212-7. PubMed ID: 20158455
[TBL] [Abstract][Full Text] [Related]
6. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination.
López-Palomo C; Martín-Zamorano M; Benítez E; Fernández-Gutiérrez C; Guerrero F; Rodríguez-Iglesias M; Girón-González JA
J Med Virol; 2004 Apr; 72(4):517-24. PubMed ID: 14981752
[TBL] [Abstract][Full Text] [Related]
7. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
[TBL] [Abstract][Full Text] [Related]
8. Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa.
Hoffmann CJ; Fielding KL; Charalambous S; Innes C; Chaisson RE; Grant AD; Churchyard GJ
AIDS; 2010 Jul; 24(11):1709-16. PubMed ID: 20495439
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of Pneumocystis carinii and community-acquired pneumonia with tobacco use in HIV disease.
Miguez-Burbano MJ; Ashkin D; Rodriguez A; Duncan R; Pitchenik A; Quintero N; Flores M; Shor-Posner G
Int J Infect Dis; 2005 Jul; 9(4):208-17. PubMed ID: 15916913
[TBL] [Abstract][Full Text] [Related]
10. Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT).
Pett SL; Carey C; Lin E; Wentworth D; Lazovski J; Miró JM; Gordin F; Angus B; Rodriguez-Barradas M; Rubio R; Tambussi G; Cooper DA; Emery S;
HIV Med; 2011 Apr; 12(4):219-27. PubMed ID: 20812949
[TBL] [Abstract][Full Text] [Related]
11. HIV-induced immune deficiency is associated with a higher risk of hepatocarcinoma, ANRS CO3 Aquitaine Cohort, France, 1998-2008.
Bruyand M; Dabis F; Vandenhende MA; Lazaro E; Neau D; Leleux O; Geffard S; Morlat P; Chêne G; Bonnet F
J Hepatol; 2011 Nov; 55(5):1058-62. PubMed ID: 21354449
[TBL] [Abstract][Full Text] [Related]
12. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.
Guiguet M; Boué F; Cadranel J; Lang JM; Rosenthal E; Costagliola D;
Lancet Oncol; 2009 Dec; 10(12):1152-9. PubMed ID: 19818686
[TBL] [Abstract][Full Text] [Related]
13. Decreasing Incidence and Determinants of Bacterial Pneumonia in People With HIV: The Swiss HIV Cohort Study.
Balakrishna S; Wolfensberger A; Kachalov V; Roth JA; Kusejko K; Scherrer AU; Furrer H; Hauser C; Calmy A; Cavassini M; Schmid P; Bernasconi E; Battegay M; Günthard HF; Kouyos RD;
J Infect Dis; 2022 May; 225(9):1592-1600. PubMed ID: 34792153
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
[TBL] [Abstract][Full Text] [Related]
15. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.
Furrer H; Egger M; Opravil M; Bernasconi E; Hirschel B; Battegay M; Telenti A; Vernazza PL; Rickenbach M; Flepp M; Malinverni R
N Engl J Med; 1999 Apr; 340(17):1301-6. PubMed ID: 10219064
[TBL] [Abstract][Full Text] [Related]
17. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
; Sterne JA; May M; Costagliola D; de Wolf F; Phillips AN; Harris R; Funk MJ; Geskus RB; Gill J; Dabis F; Miró JM; Justice AC; Ledergerber B; Fätkenheuer G; Hogg RS; Monforte AD; Saag M; Smith C; Staszewski S; Egger M; Cole SR
Lancet; 2009 Apr; 373(9672):1352-63. PubMed ID: 19361855
[TBL] [Abstract][Full Text] [Related]
18. Incidence and Risk Factors for Severe Bacterial Infections in People Living with HIV. ANRS CO3 Aquitaine Cohort, 2000-2012.
Collin A; Le Marec F; Vandenhende MA; Lazaro E; Duffau P; Cazanave C; Gérard Y; Dabis F; Bruyand M; Bonnet F;
PLoS One; 2016; 11(4):e0152970. PubMed ID: 27050752
[TBL] [Abstract][Full Text] [Related]
19. Community-acquired lower respiratory tract infections in HIV-infected patients on antiretroviral therapy: predictors in a contemporary cohort study.
Lamas CC; Coelho LE; Grinsztejn BJ; Veloso VG
Infection; 2017 Dec; 45(6):801-809. PubMed ID: 28660356
[TBL] [Abstract][Full Text] [Related]
20. The nature and consequences of cognitive deficits among tobacco smokers with HIV: a comparison to tobacco smokers without HIV.
Harrison JD; Dochney JA; Blazekovic S; Leone F; Metzger D; Frank I; Gross R; Hole A; Mounzer K; Siegel S; Schnoll RA; Ashare RL
J Neurovirol; 2017 Aug; 23(4):550-557. PubMed ID: 28429289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
